Rising student demand for new economics
From the Economist:
“I DON’T care who writes a nation’s laws, or crafts its advanced treatises, if I can write its economics textbooks.” So said Paul Samuelson, an American economist who more than achieved his aim by producing a bestseller. But debate swirls around the teaching of the dismal science—nowhere more so than in Britain.
Read more here.
A glimpse of the future economy
From the E3 Network’s Future Economy Initiative:
Source: http://www.futureecon.org/
Inequality.org
http://inequality.org/
Let them eat toxic waste?
A video made by UMass-Amherst students compares wealth-based to rights-based principles for allocating environmental quality:
Global wealth: who has how much?
The latest edition of the 2014 Global Wealth Report from Credit Suisse sheds light on the distribution of assets worldwide:
Source: http://savvyroo.com/chart-1365549786238-our-unequal-globes-billions-and-trillions
Read more here.
Inequality of opportunity
Nobel laureate Joseph Stiglitz writes:
A rich country with millions of poor people. A country that prides itself on being the land of opportunity, but in which a child’s prospects are more dependent on the income and education of his or her parents than in other advanced countries. A country that believes in fair play, but in which the richest often pay a smaller percentage of their income in taxes than those less well off. A country in which children every day pledge allegiance to the flag, asserting that there is “justice for all,” but in which, increasingly, there is only justice for those who can afford it. These are the contradictions that the United States is gradually and painfully struggling to come to terms with as it begins to comprehend the enormity of the inequalities that mark its society.
Read more here.
More on Ebola and profit-guided health care
Unusually blunt words from World Health Organization Director Margaret Chan:
Ebola emerged nearly four decades ago. Why are clinicians still empty-handed, with no vaccines and no cure?
Because Ebola has historically been confined to poor African nations. The R&D incentive is virtually non-existent. A profit-driven industry does not invest in products for markets that cannot pay. WHO has been trying to make this issue visible for ages. Now people can see for themselves.
Why no Ebola vaccine?
When the availability of health care is guided by corporate profit and state security, poor Africans just don’t count:
Almost a decade ago, scientists from Canada and the United States reported that they had created a vaccine that was 100 percent effective in protecting monkeys against the Ebola virus. The results were published in a respected journal, and health officials called them exciting. The researchers said tests in people might start within two years, and a product could potentially be ready for licensing by 2010 or 2011.
It never happened. The vaccine sat on a shelf. Only now is it undergoing the most basic safety tests in humans — with nearly 5,000 people dead from Ebola and an epidemic raging out of control in West Africa.
Its development stalled in part because Ebola is rare, and until now, outbreaks had infected only a few hundred people at a time. But experts also acknowledge that the absence of follow-up on such a promising candidate reflects a broader failure to produce medicines and vaccines for diseases that afflict poor countries. Most drug companies have resisted spending the enormous sums needed to develop products useful mostly to countries with little ability to pay.
Read more here.
core-econ
Free access to the beta version of a remarkable new textbook that aims to change economics education:
http://core-econ.org/
For a review by Econ4’s David Bollier, see here.
